13F filer · CIK 1352851 ↗
Magnetar Financial LLC
You are looking at Q3 2023. See the latest, Q2 2026 →
Reported value
$3.92B
−14% on the quarter before
Positions
435
219 new · 260 sold out
Top 10
26.1%
of the value
Est. gain
−$29.9M
on stocks held all quarter
Est. return
−1.4%
on those stocks since Q2 2023
Positions as of Sep 30, 2023, from Magnetar Financial LLC's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
The 24 largest positions, 50% of the reported value, each sized by its share, colored by what the fund did with it since Q2 2023. Striped tiles are options.
Largest buys
Since Q2 2023, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- New Relic Inc~$98.3MNew · 0.0% → 2.5%+1,148,323 shares
- Zimmer Biomet Holdings Inc~$88.0MAdded · 1.0% → 3.1%+784,219 shares
- Abcam Plc~$80.5MNew · 0.0% → 2.1%+3,559,341 shares
- Splunk Inc~$78.4MNew · 0.0% → 2.0%+536,156 shares
- Capri Holdings Limited~$69.1MNew · 0.0% → 1.8%+1,313,181 shares
- Merck & Co Inc~$65.2MAdded · 1.7% → 3.4%+632,837 shares
- Medtronic Plc~$62.2MAdded · 1.0% → 2.6%+793,987 shares
- Novartis Ag~$47.9MAdded · 0.7% → 2.1%+469,986 shares
- Denbury Inc~$46.5MNew · 0.0% → 1.2%+474,531 shares
- Intercept Pharmaceuticals In~$44.6MNew · 0.0% → 1.1%+2,407,209 shares
Largest sells
Since Q2 2023, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Nuvasive Inc~$100.9MSold out · 2.2% → 0.0%−2,427,250 shares
- Univar Solutions Inc~$99.7MSold out · 2.2% → 0.0%−2,781,342 shares
- Focus Finl Partners Inc~$95.0MSold out · 2.1% → 0.0%−1,808,576 shares
- Aerojet Rocketdyne Hldgs Inc~$92.8MSold out · 2.0% → 0.0%−1,692,146 shares
- Triton Intl Ltd~$84.3MSold out · 1.8% → 0.0%−1,012,911 shares
- Radius Global Infrastrctre I~$80.5MSold out · 1.8% → 0.0%−5,401,665 shares
- Pdc Energy Inc~$76.6MSold out · 1.7% → 0.0%−1,076,706 shares
- Arconic Corporation~$71.9MSold out · 1.6% → 0.0%−2,430,347 shares
- Iveric Bio Inc~$65.6MSold out · 1.4% → 0.0%−1,668,239 shares
- Life Storage Inc~$65.5MSold out · 1.4% → 0.0%−492,471 shares
Holdings
As of Sep 30, 2023. Changes are in shares against Jun 30, 2023, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck & Co IncCOM · shares +97% · price −10.8% | 3.4% | $132.5M | −$8.1M | ||||||||
| Zimmer Biomet Holdings IncCOM · shares +251% · price −22.9% | 3.1% | $123.0M | −$10.4M | ||||||||
| Albertsons Cos IncCOMMON STOCK · shares +1.9% · price +4.3% | 2.7% | $106.2M | +$4.3M | ||||||||
| Medtronic PlcSHS · shares +151% · price −11.1% | 2.6% | $103.4M | −$5.1M | ||||||||
| Abbott LabsCOM · shares +8.7% · price −11.2% | 2.6% | $100.1M | −$11.6M | ||||||||
| New Relic IncCOM · shares New | 2.5% | $98.3M | — | ||||||||
| Pnm Res IncCOM · shares +6.0% · price −1.1% | 2.4% | $93.6M | −$969,337 | ||||||||
| Baxter Intl IncCOM · shares +62% · price −17.2% | 2.3% | $91.4M | −$11.7M | ||||||||
| Elanco Animal Health IncCOM · shares +33% · price +11.7% | 2.3% | $88.7M | +$7.0M | ||||||||
| Churchill Capital Corp ViiCOM CL A · shares 0% · price +1.3% | 2.2% | $86.8M | +$1.1M | ||||||||
| Novartis AgSPONSORED ADR · shares +143% · price +0.9% | 2.1% | $81.5M | +$313,226 | ||||||||
| Abcam PlcADS · shares New | 2.1% | $80.5M | — | ||||||||
| Splunk IncCOM · shares New | 2.0% | $78.4M | — | ||||||||
| Activision Blizzard IncCOM · shares +5.4% · price +11.1% | 1.9% | $74.8M | +$7.1M | ||||||||
| Seagen IncCOM · shares +6.4% · price +10.2% | 1.9% | $74.1M | +$6.5M | ||||||||
| Encompass Health CorpCOM · shares −6.1% · price −0.8% | 1.8% | $71.2M | −$583,403 | ||||||||
| Capri Holdings LimitedSHS · shares New | 1.8% | $69.1M | — | ||||||||
| Vmware IncCL A COM · shares +6.7% · price +15.9% | 1.7% | $66.7M | +$8.6M | ||||||||
| Humana IncCOM · shares +27% · price +8.8% | 1.6% | $61.2M | +$3.9M | ||||||||
| Gsk PlcSPONSORED ADR · shares −8.2% · price +1.7% | 1.5% | $58.9M | +$990,371 | ||||||||
| Mckesson CorpCOM · shares +43% · price +1.8% | 1.5% | $56.8M | +$690,031 | ||||||||
| Amedisys IncCOM · shares +6.4% · price +2.1% | 1.4% | $56.8M | +$1.1M | ||||||||
| Horizon Therapeutics Pub LSHS · shares −26% · price +12.5% | 1.3% | $52.5M | +$5.8M | ||||||||
| National Instrs CorpCOM · shares 0% · price +3.9% | 1.3% | $50.4M | +$1.9M | ||||||||
| Denbury IncCOM · shares New | 1.2% | $46.5M | — | ||||||||
| Total · 435 positions | 100% | $3.92B | −$29.9M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q2 2023 to Q3 2023: 190 stocks held throughout, down $29.9M (−1.4%).
- Vmware Inc+$8.6M+16%
- Activision Blizzard Inc+$7.1M+11%
- Elanco Animal Health Inc+$7.0M+12%
- Seagen Inc+$6.5M+10%
- Horizon Therapeutics Pub L+$5.8M+12%
- Establishment Labs Hldgs Inc−$7.8M−28%
- Merck & Co Inc−$8.1M−11%
- Zimmer Biomet Holdings Inc−$10.4M−23%
- Abbott Labs−$11.6M−11%
- Baxter Intl Inc−$11.7M−17%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 14, 2026 | $10.96B+11% | SEC ↗ |
| Q1 2026 | May 13, 2026 | $9.84B−4% | SEC ↗ |
| Q4 2025 | Feb 17, 2026 | $10.21B−38% | SEC ↗ |
| Q3 2025 | Nov 13, 2025 | $16.50B−20% | SEC ↗ |
| Q2 2025 | Aug 12, 2025 | $20.65B+171% | SEC ↗ |
| Q1 2025 | May 15, 2025 | $7.61B+75% | SEC ↗ |
| Q4 2024 | Feb 11, 2025 | $4.36B−6% | SEC ↗ |
| Q3 2024 | Nov 13, 2024 | $4.62B−4% | SEC ↗ |
| Q2 2024 | Aug 14, 2024 | $4.80B+7% | SEC ↗ |
| Q1 2024 | May 15, 2024 | $4.47B+13% | SEC ↗ |
| Q4 2023 | Feb 13, 2024 | $3.94B+1% | SEC ↗ |
| Q3 2023 | Nov 14, 2023 | $3.92B−14% | SEC ↗ |
| Q2 2023 | Aug 11, 2023 | $4.56B−11% | SEC ↗ |
| Q1 2023 | May 15, 2023 | $5.13B−13% | SEC ↗ |
| Q4 2022 | Feb 14, 2023 | $5.91B−18% | SEC ↗ |
| Q3 2022 | Nov 14, 2022 | $7.21B−25% | SEC ↗ |
| Q2 2022 | Aug 15, 2022 | $9.67B+3% | SEC ↗ |
| Q1 2022 | May 16, 2022 | $9.37B−6% | SEC ↗ |
| Q4 2021 | Feb 14, 2022 | $9.96B+1% | SEC ↗ |
| Q3 2021 | Jan 14, 2022 (amended) | $9.82B−7% | SEC ↗ |
| Q2 2021 | Aug 6, 2021 | $10.56B+2% | SEC ↗ |
| Q1 2021 | May 14, 2021 | $10.40B+47% | SEC ↗ |
| Q4 2020 | Feb 12, 2021 | $7.08B+25% | SEC ↗ |
| Q3 2020 | Nov 16, 2020 | $5.66B+67% | SEC ↗ |
| Q2 2020 | Aug 14, 2020 | $3.39B−18% | SEC ↗ |
| Q1 2020 | May 15, 2020 | $4.15B−13% | SEC ↗ |
| Q4 2019 | Feb 13, 2020 | $4.79B+22% | SEC ↗ |
| Q3 2019 | Nov 14, 2019 | $3.93B−21% | SEC ↗ |
| Q2 2019 | Aug 14, 2019 | $5.00B+29% | SEC ↗ |
| Q1 2019 | May 15, 2019 | $3.89B−5% | SEC ↗ |
| Q4 2018 | Feb 14, 2019 | $4.08B−26% | SEC ↗ |
| Q3 2018 | Feb 14, 2019 (amended) | $5.54B−16% | SEC ↗ |
| Q2 2018 | Aug 14, 2018 (amended) | $6.56B+13% | SEC ↗ |
| Q1 2018 | May 15, 2018 (amended) | $5.80B+3% | SEC ↗ |
| Q4 2017 | Feb 14, 2018 (amended) | $5.62B+2% | SEC ↗ |
| Q3 2017 | Nov 14, 2017 (amended) | $5.52B−15% | SEC ↗ |
| Q2 2017 | Aug 14, 2017 (amended) | $6.52B−7% | SEC ↗ |
| Q1 2017 | May 15, 2017 (amended) | $7.02B+1,897% | SEC ↗ |
| Q4 2016 | Aug 14, 2017 (amended) | $351.5M−95% | SEC ↗ |
| Q3 2016 | Nov 14, 2016 (amended) | $7.03B+17% | SEC ↗ |
| Q2 2016 | Aug 15, 2016 (amended) | $6.02B−7% | SEC ↗ |
| Q1 2016 | May 16, 2016 (amended) | $6.49B | SEC ↗ |